- Home
- SAVA vs SIEB Comparison
SAVA vs SIEB Comparison
Compare SAVA & SIEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SIEB
- Stock Information
- Founded
- SAVA 1998
- SIEB 1886
- Country
- SAVA United States
- SIEB United States
- Employees
- SAVA N/A
- SIEB N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SIEB Investment Bankers/Brokers/Service
- Sector
- SAVA Health Care
- SIEB Finance
- Exchange
- SAVA Nasdaq
- SIEB Nasdaq
- Market Cap
- SAVA 102.4M
- SIEB 110.4M
- IPO Year
- SAVA N/A
- SIEB N/A
- Fundamental
- Price
- SAVA $3.63
- SIEB $2.93
- Analyst Decision
- SAVA Hold
- SIEB
- Analyst Count
- SAVA 1
- SIEB 0
- Target Price
- SAVA $2.00
- SIEB N/A
- AVG Volume (30 Days)
- SAVA 4.9M
- SIEB 46.0K
- Earning Date
- SAVA 11-06-2025
- SIEB 11-11-2025
- Dividend Yield
- SAVA N/A
- SIEB N/A
- EPS Growth
- SAVA N/A
- SIEB N/A
- EPS
- SAVA N/A
- SIEB 0.24
- Revenue
- SAVA N/A
- SIEB $86,037,000.00
- Revenue This Year
- SAVA N/A
- SIEB N/A
- Revenue Next Year
- SAVA N/A
- SIEB N/A
- P/E Ratio
- SAVA N/A
- SIEB $12.39
- Revenue Growth
- SAVA N/A
- SIEB 9.07
- 52 Week Low
- SAVA $1.15
- SIEB $2.08
- 52 Week High
- SAVA $33.98
- SIEB $5.77
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- SIEB 47.80
- Support Level
- SAVA $2.85
- SIEB $2.82
- Resistance Level
- SAVA $3.66
- SIEB $2.97
- Average True Range (ATR)
- SAVA 0.34
- SIEB 0.13
- MACD
- SAVA 0.10
- SIEB 0.03
- Stochastic Oscillator
- SAVA 92.90
- SIEB 29.55
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.